Structure Therapeutics is trading at $23.33, up 6.00%, amid supportive biotech-sector sentiment. - The XBI sector ETF is up 2.10% during the regular session. - Merck KGaA’s agreement to acquire Silence Therapeutics and positive clinical-trial news are supporting sector sentiment. - Structure Therapeutics announced planned presentations of aleniglipron trial data at November’s ObesityWeek on October 19; available reporting does not establish that announcement as the reason for the October 20 gain.